miRagen Therapeutics to Present a Corporate Overview at the Robert W. Baird & Co. 2019 Global Healthcare Conference
August 15 2019 - 8:00AM
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage
biopharmaceutical company developing proprietary RNA-targeted
therapies with a specific focus on microRNAs, announced today that
William S. Marshall, Ph.D., President and Chief Executive Officer,
will provide a corporate overview at the Robert W. Baird & Co.
2019 Global Healthcare Conference, which is taking place on
September 4-5 New York City.
Robert W. Baird & Co. 2019 Global
Healthcare Conference |
Date: |
Thursday, September 5 |
Time: |
8:30 a.m. Eastern Time |
Webcast: |
http://wsw.com/webcast/baird56/mgen/ |
The presentation will be webcast live and may
also be accessed by visiting the "Investors & Media" section of
the Company’s web site at www.miragen.com. A replay of the
webcast will be available for 90 days after the event.
About miRagen Therapeutics,
Inc. miRagen Therapeutics, Inc. is a clinical-stage
biopharmaceutical company discovering and developing proprietary
RNA-targeted therapies with a specific focus on microRNAs and their
role in diseases where there is a high unmet medical need. miRagen
has three clinical stage product candidates, cobomarsen, remlarsen,
and MRG-110. miRagen’s clinical product candidate for the treatment
of certain cancers, cobomarsen, is an inhibitor of microRNA-155,
which is found at abnormally high levels in malignant cells of
several blood cancers. miRagen’s clinical product candidate for the
treatment of pathological fibrosis, remlarsen, is a replacement for
microRNA-29, which is found at abnormally low levels in a number of
pathological fibrotic conditions, including cutaneous, cardiac,
renal, hepatic, pulmonary and ocular fibrosis, as well as in
systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is being
developed for the treatment of heart failure and other ischemic
disease. In addition to these programs, miRagen is developing a
pipeline of preclinical product candidates. The goal of miRagen’s
translational medicine strategy is to progress rapidly to
first-in-human studies once it has established the
pharmacokinetics, pharmacodynamic, safety, and manufacturability of
the product candidate in preclinical studies. For more information,
please visit www.miragen.com.
For information on clinical trials please visit
www.clinicaltrials.gov.
Investor/Media Contact: Dan FerryManaging
DirectorLifeSci Advisors, LLC(617) 535-7746
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024